<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="paperszoo1\PMC3192705\results\search\disease\results.xml">
  <result pre=": Infectious diseases : Viral Diseases: Influenza : Zoonoses: Avian" exact="influenza" post="A viruses Adaptation of High-Growth Influenza H5N1 Vaccine Virus"/>
  <result pre="original author and source are properly credited. Abstract Current egg-based" exact="influenza" post="vaccine production technology can't promptly meet the global demand"/>
  <result pre="production technology can't promptly meet the global demand during an" exact="influenza" post="pandemic as shown in the 2009 H1N1 pandemic. Moreover,"/>
  <result pre="capacity would be vulnerable during pandemics caused by highly pathogenic" exact="avian influenza" post="viruses. Therefore, vaccine production using mammalian cell technology is"/>
  <result pre="would be vulnerable during pandemics caused by highly pathogenic avian" exact="influenza" post="viruses. Therefore, vaccine production using mammalian cell technology is"/>
  <result pre="vaccine production using mammalian cell technology is becoming attractive. Current" exact="influenza" post="H5N1 vaccine strain (NIBRG-14), a reassortant virus between A/Vietnam/1194/2004"/>
  <result pre="generated in Vero cells, which can be used to manufacture" exact="influenza" post="H5N1 vaccines and prepare reassortant vaccine viruses for other"/>
  <result pre="influenza H5N1 vaccines and prepare reassortant vaccine viruses for other" exact="influenza" post="A subtypes. page-count: Introduction Outbreaks of avian influenza H5N1"/>
  <result pre="viruses for other influenza A subtypes. page-count: Introduction Outbreaks of" exact="avian influenza" post="H5N1 viruses emerged in 1997 and are still killing"/>
  <result pre="for other influenza A subtypes. page-count: Introduction Outbreaks of avian" exact="influenza" post="H5N1 viruses emerged in 1997 and are still killing"/>
  <result pre="transmission to humans in 2011, posing the persistent threat of" exact="influenza" post="pandemics in humans [1]. Vaccination is the most cost-effective"/>
  <result pre="Vaccination is the most cost-effective strategy to control and prevent" exact="influenza" post="pandemics and seasonal epidemics. Most current seasonal influenza vaccines"/>
  <result pre="and prevent influenza pandemics and seasonal epidemics. Most current seasonal" exact="influenza" post="vaccines are manufactured using chicken embryonated eggs, which is"/>
  <result pre="Health Organization (WHO) has been encouraging the development of cell-based" exact="influenza" post="H5N1 vaccines since 2006 [2]. Two cell lines, Vero"/>
  <result pre="lines, Vero and MDCK cells, have been licensed for manufacturing" exact="influenza" post="vaccines [3], [4], [5], [6]. In addition to influenza"/>
  <result pre="manufacturing influenza vaccines [3], [4], [5], [6]. In addition to" exact="influenza" post="vaccines, Vero cells have been widely approved for manufacturing"/>
  <result pre="other human vaccines but MDCK cells are only licensed for" exact="influenza" post="vaccines. Currently, there are four clades of influenza H5N1"/>
  <result pre="licensed for influenza vaccines. Currently, there are four clades of" exact="influenza" post="H5N1 viruses circulating in avian hosts and causing zoonotic"/>
  <result pre="clades for vaccine development and production [1]. The current clade-1" exact="influenza" post="H5N1 vaccine strain (NIBRG-14), provided from the UK NIBSC"/>
  <result pre="[8], [9], [10], [11]. Historical studies have shown that high-growth" exact="influenza" post="viruses can be selected through continuous passages and plaque"/>
  <result pre="(DPI). 10.1371/journal.pone.0024057.t001Table 1 Growth efficiency of the NIBRG-14 and Vero-adapted" exact="influenza" post="H5N1 (Vero-15) viruses with different multiplicity of infection (MOI)"/>
  <result pre="similar pattern (Table 3). 10.1371/journal.pone.0024057.t003Table 3 Growth efficiency of Vero-adapted" exact="influenza" post="H5N1 virus (Vero-15) in microcarrier-based Vero cell cultures in"/>
  <result pre="error of mean. Discussion It is well known that wild-type" exact="influenza" post="viruses and egg-adapted high-growth reasortant influenza vaccine viruses can"/>
  <result pre="well known that wild-type influenza viruses and egg-adapted high-growth reasortant" exact="influenza" post="vaccine viruses can grow efficiently in MDCK cells but"/>
  <result pre="in March 2008, more than 70 clinical trials of pandemic" exact="influenza" post="vaccines have been completed or are ongoing (www.who.int). Since"/>
  <result pre="vaccine manufacturers used the egg-based technology for production of seasonal" exact="influenza" post="vaccines and converted the egg-based facility to manufacture influenza"/>
  <result pre="seasonal influenza vaccines and converted the egg-based facility to manufacture" exact="influenza" post="H5N1 vaccines for clinical trials, only 6 clinical trials"/>
  <result pre="H5N1 virus was generated in Vero cells. Ideally, antigenicity of" exact="influenza" post="vaccine strains should be tested using ferret antisera, which"/>
  <result pre="as a master virus to generate reassortant viruses for other" exact="influenza" post="A subtypes and evaluate their growth efficiency in Vero"/>
  <result pre="in eggs are 30â€&quot;40% lower than the average of seasonal" exact="influenza" post="vaccines [22]. Howard et al., found that recent wild-type"/>
  <result pre="virus but is much higher than those of seasonal wild-type" exact="influenza" post="viruses and egg-adapted vaccine viruses [3]. In addition, these"/>
  <result pre="virus to generate vaccine seed viruses for manufacturing egg-based inactivated" exact="influenza" post="vaccines [7], [12]. One recent study showed that polymerase"/>
  <result pre="PR8 virus in Vero cells but molecular determinants of high-growth" exact="influenza" post="viruses in Vero cells have not been well defined"/>
  <result pre="Vero cells have not been well defined [19]. Our Vero-adapted" exact="influenza" post="H5N1 virus has mutations on 4 gene segments including"/>
  <result pre="original NIBRG-14 H5N1 vaccine virus. Identifying molecular determinants of high-growth" exact="influenza" post="viruses in Vero cells would be valuable for establishing"/>
  <result pre="would be valuable for establishing the platform of Vero cell-based" exact="influenza" post="vaccine production. The current global manufacturing capacity of influenza"/>
  <result pre="cell-based influenza vaccine production. The current global manufacturing capacity of" exact="influenza" post="vaccines are concentrated in Australia, Europe and North America"/>
  <result pre="America and will not meet the urgent demand during an" exact="influenza" post="pandemic, so countries without manufacturing capacity may not be"/>
  <result pre="without manufacturing capacity may not be able to have pandemic" exact="influenza" post="vaccine available [2], [25], [26]. Therefore, WHO has developed"/>
  <result pre="[2], [25], [26]. Therefore, WHO has developed a global pandemic" exact="influenza" post="action plan to increase vaccine supply. Building new production"/>
  <result pre="and cell-based culture systems are two matured technologies for manufacturing" exact="influenza" post="and other viral vaccines. The egg-based technology has long"/>
  <result pre="egg-based technology has long history of success on supplying seasonal" exact="influenza" post="vaccines but it can not be scaled-up in a"/>
  <result pre="have egg supply during a pandemic causing by highly pathogenic" exact="avian influenza" post="viruses, such as H5N1 viruses. Therefore, cell-based technology is"/>
  <result pre="egg supply during a pandemic causing by highly pathogenic avian" exact="influenza" post="viruses, such as H5N1 viruses. Therefore, cell-based technology is"/>
  <result pre="is becoming an attractive option for new facilities. A novel" exact="influenza" post="H1N1 virus emerged in March 2009 in Central America"/>
  <result pre="be the most cost-effective strategy. The urgent development of pandemic" exact="influenza" post="H1N1 vaccines raised complex challenges, especially at a time"/>
  <result pre="a time when seasonal vaccine productions were ongoing. Therefore, pandemic" exact="influenza" post="H1N1 vaccines were not available until September 2009 and"/>
  <result pre="WHO and national authorities may consider preparing for the next" exact="influenza" post="pandemic by generating Vero cell-adapted high-growth vaccine viruses with"/>
  <result pre="Vero cell-adapted high-growth vaccine viruses with pandemic potentials such as" exact="influenza" post="H2N2, H5N1, H7N7 and H9N2 and conducting clinicl trials"/>
  <result pre="of these Vero cell-derived panemic vaccine candidates. When the next" exact="influenza" post="pandemic occurs, all Vero cell culture facilities can be"/>
  <result pre="Vero cell culture facilities can be conveted to manufacture pandemic" exact="influenza" post="vaccines. Thus, global productivity of pandemic influenza vaccines will"/>
  <result pre="to manufacture pandemic influenza vaccines. Thus, global productivity of pandemic" exact="influenza" post="vaccines will be increased promptly to meet the urgent"/>
  <result pre="will be increased promptly to meet the urgent demand during" exact="influenza" post="pandemics. Materials and Methods Adaptation of NIBRG-14 in Vero"/>
  <result pre="potential use as pre-pandemic vaccines.164167 2collab: World Health Organization2006Global pandemic" exact="influenza" post="action plan to increase vaccine supplyGeneva 3KistnerOBarrettPNMundtWReiterMSchober-BendixenSet al.1998Development of"/>
  <result pre="supplyGeneva 3KistnerOBarrettPNMundtWReiterMSchober-BendixenSet al.1998Development of a mammalian cell (Vero) derived candidate" exact="influenza" post="virus vaccine.Vaccine169609689682344 4AMPHSSVdRPvEMBet al.1999Safety, reactogenicity and immunogenicity of Madin"/>
  <result pre="reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated" exact="influenza" post="subunit vaccine. A meta-analysis of clinical studies.Developments in Biological"/>
  <result pre="of cell culture vaccines in the control of the next" exact="influenza" post="pandemic.Expert Opinion on Biological Therapy470971715155162 6DoroshenkoAHalperinSA2009Trivalent MDCK cell culture-derived"/>
  <result pre="influenza pandemic.Expert Opinion on Biological Therapy470971715155162 6DoroshenkoAHalperinSA2009Trivalent MDCK cell culture-derived" exact="influenza" post="vaccine OptafluÂ® (Novartis Vaccines).Expert Review of Vaccines867968819485748 7NicolsonCMajorDWoodJMRobertsonJS2005Generation of"/>
  <result pre="influenza vaccine OptafluÂ® (Novartis Vaccines).Expert Review of Vaccines867968819485748 7NicolsonCMajorDWoodJMRobertsonJS2005Generation of" exact="influenza" post="vaccine viruses on Vero cells by reverse genetics: an"/>
  <result pre="quality system.Vaccine232943295215780743 8HorimotoTMurakamiSMuramotoYYamadaSFujiiKet al.2007Enhanced growth of seed viruses for H5N1" exact="influenza" post="vaccines.Virology366232717651774 9HuAY-CWengT-CTsengY-FChenY-SWuC-Het al.2008Microcarrier-based MDCK cell culture system for the"/>
  <result pre="9HuAY-CWengT-CTsengY-FChenY-SWuC-Het al.2008Microcarrier-based MDCK cell culture system for the production of" exact="influenza" post="H5N1 vaccines.Vaccine265736574018761387 10MKHOKPNB2008Pre-clinical development of cell culture (Vero)-derived H5N1"/>
  <result pre="moving towards cell culture-based viral vaccines.Expert Review of Vaccines860761819397417 12EDK1969Future" exact="influenza" post="vaccines and the use of genetic recombinants.Bulletin World Health"/>
  <result pre="Organ41643645 13HFMJrFTFMDAVHEMet al.1969Laboratory and clinical characteristics of attenuated strains of" exact="influenza" post="virus.Bulletin World Health Organ41589594 14NeumannGNodaTKawaokaY2009Emergence and pandemic potential of"/>
  <result pre="World Health Organ41589594 14NeumannGNodaTKawaokaY2009Emergence and pandemic potential of swine-origin H1N1" exact="influenza" post="virus.Nature45993193919525932 15GovorkovaEAKaverinNVGubarevaLVMeignierBWebsterRG1995Replication of Influenza A Viruses in a Green"/>
  <result pre="Continuous Cell Line (Vero).Journal of Infectious Diseases1722502537797924 16KaverinNWebsterR1995Impairment of multicycle" exact="influenza" post="virus growth in Vero (WHO) cells by loss of"/>
  <result pre="kidney (Vero) cells provide an alternative host cell system for" exact="influenza" post="A and B viruses.J Virol70551955248764064 18MinorPDEngelhardtOGWoodJMRobertsonJSBlayerSet al.2009Current challenges in"/>
  <result pre="and B viruses.J Virol70551955248764064 18MinorPDEngelhardtOGWoodJMRobertsonJSBlayerSet al.2009Current challenges in implementing cell-derived" exact="influenza" post="vaccines: Implications for production and regulation, July 2007, NIBSC,"/>
  <result pre="pandemic alert: use of reverse genetics for rapid development of" exact="influenza" post="vaccines.The Lancet36310991103 21SuguitanALJrMcAuliffeJMillsKLJinHDukeGet al.2006Live, Attenuated Influenza A H5N1 Candidate"/>
  <result pre="(H1N1) 2009 influenza.Vaccine275184518619563891 27PartridgeJKienyMP2010Global production of seasonal and pandemic (H1N1)" exact="influenza" post="vaccines in 2009â€&quot;2010 and comparison with previous estimates and"/>
  <result pre="action plan targets.Vaccine284709471220488262 28collab: World Health Organization2002WHO manual on animal" exact="influenza" post="diagnosis and surveillanceGenevaWorld Health Organization"/>
 </snippets>
</snippetsTree>
